Is Sarcopenia an Associated Factor of Increased Administration of Specific Medications in Patients with Heart Failure? A Systematic Review and Meta-analysis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 9

PMID 38333416

Authors

Schabnam Saied

Konstantinos Prokopidis

Adeoye Adenaya

Masoud Isanejad

Rajiv Sankaranarayanan

Affiliations

Soon will be listed here.

Abstract

Background: There is controversy in relation to commonly used drugs in heart failure (HF) and their impact on muscle function. The aim of this study was to evaluate the odds of receiving specific medications often used in clinical practice by patients with HF and sarcopenia vs. without sarcopenia.

Methods: A systematic literature search of cohort studies via databases (PubMed, Web of Science, Scopus, and Cochrane Library) was conducted from inception until March 2023. To determine if sarcopenia is linked to a higher number of specific HF-related medications, a meta-analysis using a random-effects model was used to calculate the pooled effects.

Results: Our main analyses showed no significant association of sarcopenia with administration of higher HF-related medication count vs. those without sarcopenia. Those with lower appendicular lean mass (ALM) had significantly lower odds of receiving angiotensin converting enzyme inhibitors (ACE-Is)/angiotensin receptor blockers (ARBs) (OR: 0.68, 95%CI 0.50-0.90, = 12%, < 0.01) vs. patients with higher ALM for which age could be an important confounder based on meta-regression. No statistically significant differences were found in relation to B-blockers OR: 0.84, 95%CI 0.63-1.12, = 7%, = 0.24) and loop diuretics (OR: 1.19, 95%CI 0.87-1.63, = 0%, = 0.27). Regarding handgrip strength, gait speed, and short physical performance battery, our narrative synthesis found mixed results.

Conclusion: This systematic review and meta-analysis did not find a relationship of specific medication count in sarcopenia vs. without sarcopenia in patients with HF, although increased odds of ACE-I/ARB was shown in those with higher ALM.

Systematic Review Registration: PROSPERO (CRD42023411137).

Citing Articles

Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions.

de Lima E, Tanaka M, Lamas C, Quesada K, Detregiachi C, Cressoni Araujo A Biomedicines. 2024; 12(9).

PMID: 39335609 PMC: 11428869. DOI: 10.3390/biomedicines12092096.

References

Tsuchida K, Fujihara Y, Hiroki J, Hakamata T, Sakai R, Nishida K . Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure. Int Heart J. 2018; 59(1):143-148. DOI: 10.1536/ihj.17-057. View

Kitai T, Shimogai T, Tang W, Iwata K, Xanthopoulos A, Otsuka S . Short physical performance battery vs. 6-minute walking test in hospitalized elderly patients with heart failure. Eur Heart J Open. 2022; 1(1):oeab006. PMC: 9242077. DOI: 10.1093/ehjopen/oeab006. View

Ozawa T, Yamashita M, Seino S, Kamiya K, Kagiyama N, Konishi M . Standardized gait speed ratio in elderly patients with heart failure. ESC Heart Fail. 2021; 8(5):3557-3565. PMC: 8497355. DOI: 10.1002/ehf2.13392. View

Kwak H, Thalacker-Mercer A, Anderson E, Lin C, Kane D, Lee N . Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med. 2011; 52(1):198-207. PMC: 3313473. DOI: 10.1016/j.freeradbiomed.2011.10.449. View

Ogawa A, Shimizu K, Nakagami T, Maruoka H, Shirai K . Physical Function and Cardio-Ankle Vascular Index in Elderly Heart Failure Patients. Int Heart J. 2020; 61(4):769-775. DOI: 10.1536/ihj.20-058. View

Fonseca G, Dos Santos M, de Souza F, Takayama L, Pereira R, Negrao C . Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index. ESC Heart Fail. 2019; 7(1):84-91. PMC: 7083394. DOI: 10.1002/ehf2.12545. View

Saito H, Matsue Y, Maeda D, Kasai T, Kagiyama N, Endo Y . Prognostic values of muscle mass assessed by dual-energy X-ray absorptiometry and bioelectrical impedance analysis in older patients with heart failure. Geriatr Gerontol Int. 2022; 22(8):610-615. DOI: 10.1111/ggi.14424. View

Wang L, Zheng Z, Meng L, Zhu L, Li P, Chen J . Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue. Cell Biol Toxicol. 2020; 37(3):441-460. DOI: 10.1007/s10565-020-09558-w. View

Cesari M, Pedone C, Antonelli Incalzi R, Pahor M . ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc. 2010; 11(1):26-32. PMC: 2818218. DOI: 10.1016/j.jamda.2009.09.014. View

10.

Pulignano G, Del Sindaco D, Lenarda A, Alunni G, Senni M, Tarantini L . Incremental Value of Gait Speed in Predicting Prognosis of Older Adults With Heart Failure: Insights From the IMAGE-HF Study. JACC Heart Fail. 2016; 4(4):289-98. DOI: 10.1016/j.jchf.2015.12.017. View

11.

Sumukadas D, Band M, Miller S, Cvoro V, Witham M, Struthers A . Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013; 69(6):736-43. PMC: 4022094. DOI: 10.1093/gerona/glt142. View

12.

Bieger P, Sangali T, Ribeiro E, Perry I, Souza G . Association of phase angle values and sarcopenia in older patients with heart failure. Nutr Clin Pract. 2023; 38(3):672-685. DOI: 10.1002/ncp.10956. View

13.

Chiaranda G, Bernardi E, Codeca L, Conconi F, Myers J, Terranova F . Treadmill walking speed and survival prediction in men with cardiovascular disease: a 10-year follow-up study. BMJ Open. 2013; 3(10):e003446. PMC: 3808890. DOI: 10.1136/bmjopen-2013-003446. View

14.

Harada H, Nishiyama Y, Niiyama H, Katoh A, Kai H . Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study. J Clin Pharm Ther. 2021; 47(1):89-96. DOI: 10.1111/jcpt.13540. View

15.

Onoue Y, Izumiya Y, Hanatani S, Tanaka T, Yamamura S, Kimura Y . A simple sarcopenia screening test predicts future adverse events in patients with heart failure. Int J Cardiol. 2016; 215:301-6. DOI: 10.1016/j.ijcard.2016.04.128. View

16.

Witham M, Syddall H, Dennison E, Cooper C, McMurdo M, Sayer A . ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014; 43(5):661-6. DOI: 10.1093/ageing/afu008. View

17.

Onder G, Penninx B, Balkrishnan R, Fried L, Chaves P, Williamson J . Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002; 359(9310):926-30. DOI: 10.1016/s0140-6736(02)08024-8. View

18.

Lin C, Chang P, Chu P, Chuang Y, Huang R, Chen C . Effects of losartan and exercise on muscle mass and exercise endurance of old mice. Exp Gerontol. 2022; 165:111869. DOI: 10.1016/j.exger.2022.111869. View

19.

Chen R, Xu J, Wang Y, Jiang B, Xu X, Lan Y . Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review. Clin Cardiol. 2023; 46(3):260-268. PMC: 10018088. DOI: 10.1002/clc.23970. View

20.

Peng J, Gong H, Lyu X, Liu Y, Li S, Tan S . Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia. Front Cell Infect Microbiol. 2023; 13:1127041. PMC: 9998919. DOI: 10.3389/fcimb.2023.1127041. View